News that Eli Lilly and Co has forecast a drop in 2014 profits and
reduced its sales outlook because of generic competition to its Cymbalta antidepressant
and Evista drug for osteoporosis, underlines the challenges
that pharma companies face when patents expire.
Read the full article here:
http://www.pmlive.com/digital_handbook/online_audiences/online_physician_communities/maximising_roi_from_mature_brands/